Our studies involving multiple mouse tumor models indicate that combining an SV vector with agonistic antibodies to OX40 (αOX40) can confer complete remission and protection from recurrence by driving activated T cells selectively into the TME [1,12,13]. The gene discussed is TNFRSF4; the disease is neoplasm.